IL161915A0 - Salt forms of methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)- quinazolin-6-yl)-allyl)-acetamide, its prepar - Google Patents

Salt forms of methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)- quinazolin-6-yl)-allyl)-acetamide, its prepar

Info

Publication number: IL161915A0
Authority: IL; Israel
Prior art keywords: yloxyl; prepar; quinazolin; phenylamino; pyridin
Prior art date: 2001-12-12

Application number

IL16191502A

Other languages

English (en)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-12

Filing date

2002-11-11

Publication date

2005-11-20

2002-11-11 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-11-20 Publication of IL161915A0 publication Critical patent/IL161915A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL16191502A 2001-12-12 2002-11-11 Salt forms of methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)- quinazolin-6-yl)-allyl)-acetamide, its prepar IL161915A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34088501P	2001-12-12	2001-12-12
PCT/IB2002/004708 WO2003050108A1 (fr)	2001-12-12	2002-11-11	Formes salines de e-2-methoxy-n-(3-{4-[3-methl-4-(6-methylpyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide

Publications (1)

Publication Number	Publication Date
IL161915A0 true IL161915A0 (en)	2005-11-20

Family

ID=23335337

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16191502A IL161915A0 (en)	2001-12-12	2002-11-11	Salt forms of methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)- quinazolin-6-yl)-allyl)-acetamide, its prepar

Country Status (34)

Country	Link
US (1)	US6844349B2 (fr)
EP (1)	EP1456199A1 (fr)
JP (1)	JP4202926B2 (fr)
KR (1)	KR20040065259A (fr)
CN (1)	CN1608062A (fr)
AP (1)	AP2004003059A0 (fr)
AR (1)	AR037772A1 (fr)
AU (1)	AU2002366581A1 (fr)
BR (1)	BR0214876A (fr)
CA (1)	CA2469889A1 (fr)
DO (1)	DOP2002000544A (fr)
EA (1)	EA007412B1 (fr)
EC (1)	ECSP045148A (fr)
GE (1)	GEP20063872B (fr)
GT (1)	GT200200272A (fr)
HR (1)	HRP20040530A2 (fr)
HU (1)	HUP0402662A2 (fr)
IL (1)	IL161915A0 (fr)
IS (1)	IS7227A (fr)
MA (1)	MA27095A1 (fr)
MX (1)	MXPA04005678A (fr)
NO (1)	NO20042925L (fr)
NZ (1)	NZ532436A (fr)
OA (1)	OA12735A (fr)
PA (1)	PA8561401A1 (fr)
PE (1)	PE20030716A1 (fr)
PL (1)	PL370858A1 (fr)
RS (1)	RS46404A (fr)
TN (1)	TNSN04112A1 (fr)
TW (1)	TW200301103A (fr)
UA (1)	UA75482C2 (fr)
UY (1)	UY27572A1 (fr)
WO (1)	WO2003050108A1 (fr)
ZA (1)	ZA200402995B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20040529A2 (en) *	2001-12-12	2004-10-31	Pfizer Prod Inc	Quinazoline derivatives for the treatment of abnormal cell growth
EP1521747B1 (fr)	2002-07-15	2018-09-05	Symphony Evolution, Inc.	Modulateurs de kinase de type recepteur et procedes d'utilisation
RU2005119172A (ru) *	2002-12-18	2006-01-20	Пфайзер Продактс Инк. (Us)	Производные 4-анилинхиназолина для лечения патологического роста клеток
RU2005122659A (ru) *	2002-12-19	2006-01-20	Пфайзер Продактс Инк. (Us)	Комплексы е-2-метокси-n-(3-{4-[3-метил-4-(6-метилпиридин-3-илокси) фениламино] хиназолин-6-ил} аллил) ацетамида, способ получения и применения указанных комплексов
US7429565B2 (en)	2003-04-25	2008-09-30	Gilead Sciences, Inc.	Antiviral phosphonate analogs
KR20060037447A (ko) *	2003-08-18	2006-05-03	화이자 프로덕츠 인크.	ｅｒｂＢ２ 항암제에 대한 투약 스케쥴
ES2925655T3 (es)	2003-09-26	2022-10-19	Exelixis Inc	Moduladores c-Met y métodos de uso
CA2543201C (fr) *	2003-10-27	2010-12-21	Merck & Co., Inc.	Sel de succinate de ((ir, 3s)-3-isopropyl-3-{ [3-(trifluoromethyl)-7, 8-dihydro-1, 6-naphthyridin-6 (5h)- yl] carbonyl} cyclopentyl) [(3s, 4s)-3-methoxytetrahydro-2h-pyran-4-yl] amine, sa composition et son utilisation dans le traitemetn des maladies inflammatoires
US20050192298A1 (en) *	2004-02-27	2005-09-01	Pfizer Inc	Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
WO2005121124A1 (fr) *	2004-06-07	2005-12-22	Pfizer Products Inc.	Complexes de e-2-methoxy-n-(3-{4-[3-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide et procedes de preparation de ces derniers
HRP20070078A2 (hr)	2004-07-27	2007-05-31	Gilead Sciences	Fosfonatni analozi spojeva koji inhibiraju hiv
EP1896451A2 (fr) *	2005-06-03	2008-03-12	Pfizer Products Incorporated	Derives bicycliques pour le traitement de croissance cellulaire anormale
CA2610661A1 (fr) *	2005-06-03	2006-12-07	Pfizer Products Inc.	Combinaisons d'inhibiteurs d'erbb2 avec d'autres agents therapeutiques dans le traitement du cancer
PT2020996E (pt) *	2006-05-16	2012-02-20	Gilead Sciences Inc	Método e composições para tratar neoplasias malignas hematológicas
CA2673097A1 (fr)	2006-12-12	2008-06-19	Takeda Pharmaceutical Company Limited	Compose heterocyclique condense
CN101611029B (zh) *	2006-12-21	2014-09-10	辉瑞产品公司	2-((4-(1-甲基-4-(吡啶-4-基)-1h-吡唑-3-基)苯氧基)甲基)喹啉的琥珀酸盐
WO2008124824A1 (fr) *	2007-04-10	2008-10-16	Myriad Genetics, Inc.	Doses et méthodes de traitement du cancer
TW200944528A (en)	2008-03-12	2009-11-01	Takeda Pharmaceutical	Fused heterocyclic compound
PT2307435E (pt) *	2008-07-08	2012-09-19	Gilead Sciences Inc	Sais de compostos inibidores de vih
KR20250123237A (ko)	2009-01-16	2025-08-14	엑셀리시스, 인코포레이티드	암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011153050A1 (fr)	2010-06-02	2011-12-08	The Trustees Of The University Of Pennsylvania	Méthodes et utilisation de composés qui se lient au complexe du récepteur her2/neu
US8993634B2 (en)	2010-06-02	2015-03-31	The Trustees Of The University Of Pennsylvania	Methods and use of compounds that bind to Her2/neu receptor complex
US9526648B2 (en)	2010-06-13	2016-12-27	Synerz Medical, Inc.	Intragastric device for treating obesity
US10010439B2 (en)	2010-06-13	2018-07-03	Synerz Medical, Inc.	Intragastric device for treating obesity
US8628554B2 (en)	2010-06-13	2014-01-14	Virender K. Sharma	Intragastric device for treating obesity
US10420665B2 (en)	2010-06-13	2019-09-24	W. L. Gore & Associates, Inc.	Intragastric device for treating obesity
US9468681B2 (en)	2013-03-01	2016-10-18	California Institute Of Technology	Targeted nanoparticles
CN111643479B (zh)	2015-07-01	2023-10-27	加州理工学院	基于阳离子粘酸聚合物的递送系统
US10779980B2 (en)	2016-04-27	2020-09-22	Synerz Medical, Inc.	Intragastric device for treating obesity
WO2019027920A1 (fr)	2017-08-01	2019-02-07	Gilead Sciences, Inc.	Formes cristallines d'éthyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)méthyl)(phénoxy)phosphoryl)-l-alaninate (gs-9131) pour le traitement d'infections virales
WO2019241327A1 (fr)	2018-06-13	2019-12-19	California Institute Of Technology	Nanoparticules permettant de traverser la barrière hématoencéphalique et méthodes de traitement faisant appel à celle-ci
JP7187733B2 (ja) *	2020-07-06	2022-12-12	キッセイ薬品工業株式会社	オクタヒドロチエノキノリン化合物のコハク酸塩及びその結晶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6884418B1 (en)	1989-08-04	2005-04-26	Berlex Laboratories, Inc.	Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
EP0912559B1 (fr) *	1996-07-13	2002-11-06	Glaxo Group Limited	Composes heterocycliques condenses en tant qu'inhibiteurs de la proteine tyrosine kinase
JP4044839B2 (ja) *	2000-06-22	2008-02-06	ファイザー・プロダクツ・インク	異常細胞増殖を治療するための置換２環式誘導体

2002
- 2002-11-11 WO PCT/IB2002/004708 patent/WO2003050108A1/fr not_active Ceased
- 2002-11-11 HU HU0402662A patent/HUP0402662A2/hu unknown
- 2002-11-11 NZ NZ532436A patent/NZ532436A/en unknown
- 2002-11-11 RS YU46404A patent/RS46404A/sr unknown
- 2002-11-11 EA EA200400674A patent/EA007412B1/ru not_active IP Right Cessation
- 2002-11-11 PL PL02370858A patent/PL370858A1/xx not_active Application Discontinuation
- 2002-11-11 AP APAP/P/2004/003059A patent/AP2004003059A0/en unknown
- 2002-11-11 EP EP02804543A patent/EP1456199A1/fr not_active Withdrawn
- 2002-11-11 UA UA20040604566A patent/UA75482C2/uk unknown
- 2002-11-11 BR BR0214876-5A patent/BR0214876A/pt not_active IP Right Cessation
- 2002-11-11 AU AU2002366581A patent/AU2002366581A1/en not_active Abandoned
- 2002-11-11 IL IL16191502A patent/IL161915A0/xx unknown
- 2002-11-11 JP JP2003551132A patent/JP4202926B2/ja not_active Expired - Fee Related
- 2002-11-11 HR HR20040530A patent/HRP20040530A2/hr not_active Application Discontinuation
- 2002-11-11 CN CNA028248554A patent/CN1608062A/zh active Pending
- 2002-11-11 GE GE5562A patent/GEP20063872B/en unknown
- 2002-11-11 CA CA002469889A patent/CA2469889A1/fr not_active Abandoned
- 2002-11-11 KR KR10-2004-7009073A patent/KR20040065259A/ko not_active Ceased
- 2002-11-11 OA OA1200400161A patent/OA12735A/en unknown
- 2002-11-11 MX MXPA04005678A patent/MXPA04005678A/es active IP Right Grant
- 2002-12-06 TW TW091135465A patent/TW200301103A/zh unknown
- 2002-12-09 UY UY27572A patent/UY27572A1/es not_active Application Discontinuation
- 2002-12-10 US US10/315,862 patent/US6844349B2/en not_active Expired - Fee Related
- 2002-12-10 PE PE2002001185A patent/PE20030716A1/es not_active Application Discontinuation
- 2002-12-10 DO DO2002000544A patent/DOP2002000544A/es unknown
- 2002-12-10 AR ARP020104779A patent/AR037772A1/es unknown
- 2002-12-12 GT GT200200272A patent/GT200200272A/es unknown
- 2002-12-12 PA PA20028561401A patent/PA8561401A1/es unknown
2004
- 2004-04-19 IS IS7227A patent/IS7227A/is unknown
- 2004-04-20 ZA ZA200402995A patent/ZA200402995B/en unknown
- 2004-06-08 MA MA27730A patent/MA27095A1/fr unknown
- 2004-06-11 EC EC2004005148A patent/ECSP045148A/es unknown
- 2004-06-11 TN TNP2004000112A patent/TNSN04112A1/fr unknown
- 2004-07-09 NO NO20042925A patent/NO20042925L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EA200400674A1 (ru)	2004-10-28
DOP2002000544A (es)	2003-06-16
UA75482C2 (en)	2006-04-17
OA12735A (en)	2006-06-29
TNSN04112A1 (fr)	2006-06-01
US20030158217A1 (en)	2003-08-21
NO20042925L (no)	2004-09-07
MA27095A1 (fr)	2004-12-20
HUP0402662A2 (hu)	2005-05-30
MXPA04005678A (es)	2004-12-06
JP4202926B2 (ja)	2008-12-24
PA8561401A1 (es)	2005-02-04
AU2002366581A1 (en)	2003-06-23
GEP20063872B (en)	2006-07-10
WO2003050108A8 (fr)	2003-12-18
RS46404A (sr)	2006-10-27
EA007412B1 (ru)	2006-10-27
BR0214876A (pt)	2004-12-28
PL370858A1 (en)	2005-05-30
PE20030716A1 (es)	2003-08-29
KR20040065259A (ko)	2004-07-21
AR037772A1 (es)	2004-12-01
UY27572A1 (es)	2003-07-31
CN1608062A (zh)	2005-04-20
ZA200402995B (en)	2005-04-20
GT200200272A (es)	2003-12-12
WO2003050108A1 (fr)	2003-06-19
HRP20040530A2 (en)	2004-10-31
AP2004003059A0 (en)	2004-06-30
US6844349B2 (en)	2005-01-18
IS7227A (is)	2004-04-19
JP2005511744A (ja)	2005-04-28
NZ532436A (en)	2006-01-27
ECSP045148A (es)	2004-07-23
TW200301103A (en)	2003-07-01
EP1456199A1 (fr)	2004-09-15
CA2469889A1 (fr)	2003-06-19

Publication	Publication Date	Title
IL161915A0 (en)	2005-11-20	Salt forms of methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)- quinazolin-6-yl)-allyl)-acetamide, its prepar
DE60233833D1 (de)	2009-11-05	Hautfreundliches hakenförmiges Befestigungselement
EP1451156A4 (fr)	2005-05-25	Composes 4-aminoquinoleines
DK1451192T3 (da)	2011-04-04	Ny krystallinsk forbindelse
AU2002312370A1 (en)	2002-12-23	Antipathogenic benzamide compounds
IL157109A0 (en)	2004-02-08	Quinazolines as mmp-13 inhibitors
AU2003213092A8 (en)	2003-09-09	Syntheses of quinazolinones
HUP0401248A3 (en)	2004-11-29	Preparation of aminopyrimidine compounds and new intermediates
PL378576A1 (pl)	2006-05-02	Wytwarzanie podstawionych chinazolin
DE60201799D1 (de)	2004-12-09	Lösbares Befestigungsclip
EP1558260A4 (fr)	2006-10-25	Composes de quinazolinone utilises comme calcilytiques
IS7287A (is)	2004-05-26	Pýrimídín efnasambönd
IS6868A (is)	2003-07-08	Ný pýrimidínefnasambönd
NO20035573L (no)	2004-02-16	Kinazolinderivater
IL213960A0 (en)	2011-08-31	2-(substituted phenyl)-2-hydroxyl -ethyl carbamates
NO20035713L (no)	2004-02-18	Forbindelsesforankring
AU2002359574A8 (en)	2003-06-23	Antisense modulation of g protein-coupled receptor etbr-lp-2 expression
DE60126734D1 (de)	2007-04-05	Superiostealer Knochenanker
NO20042613L (no)	2004-08-13	Ny anvendelse for behandling av gastroosofagial refluks
GB0102900D0 (en)	2001-03-21	Surveying of boreholes
GB0112322D0 (en)	2001-07-11	Synthesis of chiral intermediates
FI20012552A0 (fi)	2001-12-21	Metallikarbonaatin valmistusmenetelmä
FI20011519A0 (fi)	2001-07-11	Protokollaperusteiset päätelaitevaltuutukset
TW545172U (en)	2003-08-01	Improved structure of thermostatic barrel
DK200100218U3 (da)	2001-11-09	Overfladebelægning af sten